Korro Bio Q2 net loss $18.9M, cash $137.9M; exchanges 1M shares for pre-funded warrants

Korro Bio, Inc.

Net loss $18.9M for Q2 2026 vs $25.8M in Q2 2025; no collaboration revenue due to Novo Nordisk pause.
Cash, equivalents and marketable securities $137.9M as of June 30, 2026; runway into H2 2028.
Exchange agreement: VenRock surrenders 1M shares for pre-funded warrants at $0.001 exercise price, no expiration.
KRRO-121 on track for first-in-human trial H2 2026; received EMA Orphan Drug Designation for UCDs.
Nominated KRRO-111 for AATD; preclinical data shows >90% editing and ~95% reduction of Z-AAT aggregates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.